Adjuvant docetaxel for high-risk, node-negative breast cancer.

@article{Martn2010AdjuvantDF,
  title={Adjuvant docetaxel for high-risk, node-negative breast cancer.},
  author={Miguel Mart{\'i}n and Miguel Segu{\'i} and Antonio J. Monroy Ant{\'o}n and A Pastrana Ruiz and Manuel Gil Ramos and Encarna Adrover and Ignacio Aranda and Alvaro Rodr{\'i}guez-Lescure and Regina Grosse and Lourdes Calvo and Agust{\'i} Barnadas and Dolores Isla and Purificaci{\'o}n Mart{\'i}nez del Prado and Manuel Ru{\'i}z Borrego and Jerzy Zaluski and Angels Arcusa and Montserrat Palma i Mu{\~n}oz and Jos{\'e} Manuel L{\'o}pez Vega and Jos{\'e} Ram{\'o}n Mel and Blanca Mun{\'a}rriz and Cristina Ayela Llorca and Carlos Andr{\'e}s Tamayo Jara and Emilio Ortiz Alba and Jes{\'u}s Flori{\'a}n and Junfang Li and Jos{\'e} Antonio L{\'o}pez Garc{\'i}a-Asenjo and Amparo S{\'a}ez and Mar{\'i}a Jos{\'e} Lazo R{\'i}os and Sergio M Almenar and Gl{\`o}ria Peir{\'o} and Ana Lluch},
  journal={The New England journal of medicine},
  year={2010},
  volume={363 23},
  pages={
          2200-10
        }
}
BACKGROUND A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined. METHODS We randomly assigned 1060 women with axillary-node-negative breast cancer and at least one high-risk factor for recurrence (according to the 1998 St. Gallen criteria) to… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 93 CITATIONS, ESTIMATED 55% COVERAGE

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 6 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer.

  • Medicinski glasnik : official publication of the Medical Association of Zenica-Doboj Canton, Bosnia and Herzegovina
  • 2019
VIEW 1 EXCERPT
CITES METHODS

FILTER CITATIONS BY YEAR

2011
2019

CITATION STATISTICS

  • 4 Highly Influenced Citations

  • Averaged 4 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 24 REFERENCES

: pooled analysis of 15 , 500 patients

S Jones, FA Holmes, J O’Shaughnessy
  • 2006